Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2014-03-13
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 37
- Registration Number
- NCT02086604
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Ohio State University, James Cancer Hospital, Columbus, Ohio, United States
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Refractory Diffuse Large B-Cell LymphomaRelapsed Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 138
- Registration Number
- NCT02077166
- Locations
- 🇺🇸
Baylor Charles Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Weill Cornell Medical Center, New York, New York, United States
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: lenalidomideBiological: pidilizumabOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2023-01-27
- Target Recruit Count
- 20
- Registration Number
- NCT02077959
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 569
- Registration Number
- NCT02076009
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 3
- Registration Number
- NCT02075021
- Locations
- 🇺🇸
NYU School of Medicine, New York, New York, United States
Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 92
- Registration Number
- NCT02060656
- Locations
- 🇬🇧
Royal Marsden NHS Foundation Trust - London and Surrey, London, United Kingdom
Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Boston VA Research Institute, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT02041325
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸VA Boston Healthcare System, Boston, Massachusetts, United States
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Interventions
- Other: Laboratory Biomarker AnalysisDrug: Lenalidomide
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- Albert Einstein College of Medicine
- Target Recruit Count
- 3
- Registration Number
- NCT02038153
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸Montefiore Medical Center - Moses Campus, Bronx, New York, United States
A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 77
- Registration Number
- NCT02036502
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 9
- Registration Number
- NCT02030483
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.